Protocol Ledger

NCT05653427 · Phase II · TERMINATED

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Interventional Phase II clinical trial protocol NCT05653427 sponsored by Johnson & Johnson / Janssen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-08 Enrollment: 18 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05653427
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)18 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05653427
Protocol FieldVerified Registry Value
NCT IdentifierNCT05653427
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment18 participants (ACTUAL)
Registered Start Date2022-12-08
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05653427
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Chongqing Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->
Zhejiang Cancer HospitalHangzhou, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI